Viewing Study NCT06394206



Ignite Creation Date: 2024-05-06 @ 8:27 PM
Last Modification Date: 2024-10-26 @ 3:28 PM
Study NCT ID: NCT06394206
Status: NOT_YET_RECRUITING
Last Update Posted: 2024-05-01
First Post: 2024-04-25

Brief Title: Benefit of a Hospital Intervention in Patients With Hepatic Steatosis
Sponsor: Consorci Sanitari de lAlt Penedès i Garraf
Organization: Consorci Sanitari de lAlt Penedès i Garraf

Study Overview

Official Title: Benefit of a Hospital Intervention in Patients With Hepatic Steatosis
Status: NOT_YET_RECRUITING
Status Verified Date: 2024-04
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: BIPEH
Brief Summary: The objective of this clinical trial is to determine whether a specialized consultation for controlling metabolic syndrome effectively treats hepatic steatosis in adults The primary questions it aims to answer are

Does this specialized consultation increase the number of patients with hepatic steatosis who show improvement after one year of clinical follow-up in said consultation

The improvement of the disease will be assessed through the following parameters

liver laboratory tests
weight loss
improvement in cholesterol and triglyceride levels Researchers will compare follow-up in the specialized consultation to standard follow-up to assess the effectiveness of the specialized consultation in treating hepatic steatosis

Participants will be randomly assigned to two groups The first group will be visited in the specialized consultation every three months for one year and will continue to receive the rest of their follow-up visits The second group will undergo their usual follow-up visits but will not be visited in the specialized consultation
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None